Context Plans To Report CTIM-76 Interim Phase 1a Data In June 2026; FY25 Net Loss Widens

AI Briefing

• – Context Therapeutics Inc. reports wider net loss for FY25, outlines pipeline milestones.
• – Company to report CTIM-76 interim phase 1a data in June 2026.
• – Investigational pipeline targets solid tumours.